Did you know? You can suggest edits to improve this peptide information.
Overview
What is Sermorelin?
Sermorelin acetate is a 29-amino acid synthetic analog of human growth hormone-releasing hormone (GHRH) originally FDA-approved in 1997 for pediatric growth hormone deficiency. Despite discontinuation in 2008 for manufacturing reasons, it maintains excellent safety profile and stimulates natural growth hormone production while preserving physiological pulsatile patterns.
Key Benefits
FDA-proven efficacy, 6% bioavailability, maintains natural GH pulses, preserves pituitary function
Mechanism of Action
Subcutaneous injection provides optimal bioavailability with rapid onset (5-20 minutes) and physiological pulsatile GH stimulation
Pharmacokinetics
Research Indications
Lean Body Mass Enhancement
1.26 kg lean mass increase documented in elderly men with improved muscle strength tests
IGF-1 Mediated Growth
Stimulates endogenous IGF-1 production leading to muscle protein synthesis and growth
Athletic Performance Support
Enhanced recovery and muscle development through physiological GH stimulation
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Bedtime administration aligns with natural nocturnal GH pulses. Avoid food 2+ hours before injection as carbohydrates blunt GH response. Morning administration less effective.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Allow sermorelin vial to reach room temperature before reconstitution
Clean vial top with alcohol swab and allow to dry
Inject 3mL bacteriostatic water slowly against vial wall (not directly onto powder)
Gently swirl vial in circular motion - do not shake vigorously to avoid foaming
Allow to sit for 2-3 minutes until powder completely dissolves into clear solution
Store reconstituted solution at 2-8°C and use within 10-30 days depending on formulation
Inject subcutaneously at 45-degree angle rotating between lower abdomen, thigh, and upper arm sites
Quality Indicators
Clear reconstituted solution
Should be completely clear and colorless without particles, cloudiness, or precipitation
Pharmaceutical grade purity
Greater than 98% peptide purity per USP standards with sterile, nonpyrogenic lyophilized powder
Proper cold chain storage
Maintained at 2-8°C throughout transport with protection from light and temperature extremes
FDA-registered manufacturing
Produced in FDA-registered facilities following current Good Manufacturing Practices with third-party verification
Cloudy or discolored solution
Any cloudiness, particles, color changes, or precipitation indicates degradation or contamination
Incorrect molecular weight
Should be exactly 3,358 daltons (free base) or 3,418 daltons (acetate salt) - verify with COA
Room temperature exposure
Brief room temperature exposure acceptable up to 72 hours but should be refrigerated promptly
What to Expect
- Week 1-2: IGF-1 levels begin to rise, possible improved sleep quality and recovery
- Week 2-4: Enhanced body composition changes begin, increased energy and well-being
- Week 4-8: Visible muscle tone improvements, fat reduction, skin quality enhancement
- Week 8-12: Sustained body composition improvements, optimal IGF-1 elevation achieved
- Month 3-6: Maximum benefits including muscle growth, fat loss, and anti-aging effects
Side Effects & Safety
- Monitor thyroid function - 6.5% develop hypothyroidism requiring hormone replacement
- Check IGF-1 levels monthly initially, then every 3-6 months long-term
- Injection site reactions occur in 16.7% of patients but are generally mild
- Contraindicated in active malignancy, pituitary tumors, and pregnancy
References
Nasal Administration Study (1990s)
Clinical study demonstrating effective nasal delivery with patient preference benefits and direct absorption via nasal capillaries
View Study (opens in new tab) →Synergistic Effects with GHRP-2 (Clinical)
Study demonstrating significant synergistic effects when combining GHRH analogs with growth hormone releasing peptides
View Study (opens in new tab) →FDA Approval Study - Pediatric GH Deficiency (1996)
Pivotal Geref International Study Group trial with 110 prepubertal GH-deficient children demonstrating sustained efficacy through 36 months of treatment
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia